A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination with Pembrolizumab in Participants with Selected Locally Advanced or Metastatic Solid Tumors

Protocol No
TEVA-TV56278-ONC-10203
Staff Member
Deepak Kilari
Phase
I
Summary

The purpose of this research study is to learn about the safety and effects of the study medicine, TEV-56278 in adults, to find the best dose and determine if TEV-56278 will help stabilize, limit, or slow the worsening of the cancer type you have been diagnosed with.
Objective
A Phase 1A 1B Study of TEV-56278 in Patients with Selected Locally Advanced or Metastatic Solid Tumors
Study Sites
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
Cancer, Bladder, Lung, Cervix, Lip, Oral Cavity and Pharynx, Gastrointestinal Cancers, Other Skin, Larynx, Kidney, Melanoma, Skin, Gynecologic Cancers, Thoracic Cancers, Skin Cancers, Breast Cancers, Head and Neck Cancers, Prostate and Urologic Cancers
ClinicalTrials.gov
https://www.clinicaltrials.gov/study/NCT06480552